2019Q4 1 post

• Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued
  8 February 2020  ·  Diabetes Eli Lilly LLY
  The revenue from anti-diabetic drugs in the US is flat across companies such as Novo Nordisk, Eli Lilly, Merck and Sanofi despite the growth of Ozempic ® due to declining sales of Lantus ® (insulin glargine from Sanofi), Victoza ® (GLP1 liraglutide from Novo Nordisk), Levemir ® (insulin detemir from